Signia Therapeutics

Description: Signia Therapeutics repurposes marketed drugs into fast, cost-effective antivirals for respiratory viruses, targeting host-cells for rapid phase II trials.

Country: France

Based in: Villeurbanne

Founded: 2017

Funding Stage: Series A/B

Tags: ['Therapeutics', 'marketed drugs', 'antiviral', 'respiratory viruses']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.